Exhibit 99.1

Monday October 1, 8:30 am Eastern Time

Press Release

SOURCE: Targeted Genetics Corporation

Targeted Genetics Appoints Chief Financial Officer

SEATTLE, Oct. 1 /PRNewswire/ -- Targeted Genetics Corporation (Nasdaq: TGEN -
news) today announced the appointment of Todd E. Simpson to the position of Vice
President, Finance and Administration, and Chief Financial Officer. Mr. Simpson
brings 18 years of financial management experience to the Company.

Mr. Simpson most recently served as Vice President, Finance & Administration and
Chief Financial Officer of Aastrom Biosciences, Inc., a publicly held cell
therapy company. At Aastrom, he led the completion of numerous public and
private financings totaling nearly $70 million and was instrumental in the
development and implementation of strategic planning as well as operations.
Previously he was Vice President Finance of Telios Pharmaceuticals, Inc., a
publicly held life sciences company. From 1983 to 1992 he practiced public
accounting at Ernst & Young, LLP, focusing in the life sciences industry among
others. He holds a B.S. in Business Administration and Computer Science from
Oregon State University and is a certified public accountant.

"Todd's experience and expertise in the biotech financial world will benefit
Targeted Genetics significantly and made him the candidate of choice for this
position," said H. Stewart Parker, the Company's President and Chief Executive
Officer. "His contacts in, and understanding of, the financial community have
enabled him to lead successful financing transactions, even in difficult
markets. Additionally, his operations experience will be a great asset to us as
we move forward with the plans for our large-scale AAV manufacturing facility in
Bothell and continue to build upon our leadership position in gene therapy. I
have always believed that Targeted Genetics has one of the most talented
management teams in the business, and Todd is of that caliber. We all look
forward to working together towards bringing new therapies to patients in need
and building value for our shareholders."

"I believe that Targeted Genetics is positioned for growth and I am tremendously
pleased to have the opportunity to join the Company," said Mr. Simpson. "Gene
therapy, already understood to hold enormous potential in the treatment of
genetic diseases, is beginning to be appreciated by a broader audience as the
technology is seen as a novel approach to delivering protein therapeutics.
Success in this arena will require the ability to integrate genes and vectors in
order to target a desired cell population and achieve a therapeutic effect. I
believe that Targeted Genetics' combination of viral and non-viral delivery
vectors, portfolio of genes and high-caliber partnerships and strategic
relationships uniquely position the Company for success. These important assets,
coupled with the Company's robust and diverse portfolio of product candidates,
should enable Targeted Genetics to create additional value and further
differentiate the Company as the leading gene delivery franchise."

Targeted Genetics Corporation develops gene therapy products for the treatment
of acquired and inherited diseases. The Company has lead clinical product
development programs targeting cystic fibrosis and cancer, and a promising
pipeline of product candidates focused on hemophilia A, arthritis, cancer,
lysosomal storage diseases, cardiovascular disease and AIDS prophylaxis. The
Company has a broad platform of gene delivery technologies and, through its
majority-owned



subsidiary, CellExSys, Inc., a promising body of technology for cellular
therapy. For more information about Targeted Genetics Corporation and CellExSys,
Inc., please visit the Company's web site at http://www.targetedgenetics.com.

NOTE: This release contains forward-looking statements, which involve current
expectations or forecasts of future events and other statements that are not
historical facts. Inaccurate assumptions and known or unknown risks and
uncertainties can affect the accuracy of forward-looking statements. Actual
results could differ materially from those expressed in the forward-looking
statements for a number of reasons, including the factors described in the
section entitled "Factors Affecting Our Operating Results, Our Business and Our
Stock Price" in the Company's quarterly report on Form 10-Q for the quarter
ended June 30, 2001, filed with the SEC. You should not unduly rely on these
forward-looking statements, which speak only as of the date of this release.
Targeted Genetics undertakes no obligation to update any forward-looking
statements to reflect new information, circumstances or events after the date of
this release.

SOURCE: Targeted Genetics Corporation


                                       2